University of Utah Health publishes a wide range of services for midlife and menopause, including nonhormonal therapies. The list also contains psychotherapy, pelvic floor care, nutrition counseling and health coaching. Its breadth makes the purpose of each proposed service more important, not less: a reader still needs to know what change is being sought.
This review was completed September 29, 2026. It examines the program’s documented offering, the information requested before a visit and the limits of applying treatment evidence across different goals. It does not convert the service list into a personal treatment plan or confirm a particular nonhormonal medicine.
Name the outcome before choosing a service category
Utah’s program overview covers hot flashes, sleep concerns, vaginal symptoms, sexual difficulties and other changes. It lists hormonal, nonhormonal and off-label approaches among possible treatments. That confirms a relevant clinical offering, but it does not explain which intervention would be chosen for a particular person.
The visit-goals guide distinguishes the symptom someone wants help with from the treatment family eventually discussed. At Utah, that distinction could separate reducing hot-flash disruption from addressing painful sex or understanding sleep problems. A service can have value for one of those purposes without being evidence that the same approach improves them all.
Behavioral services need more precise names
The Utah treatment list includes behavioral therapy, psychotherapy and sex therapy, as well as wellness programs and health coaching. These descriptions identify services, not a single standardized intervention. Their inclusion does not establish the specific techniques, number of appointments or evidence relevant to an individual goal.
The 2023 NAMS statement abstract recommends cognitive behavioral therapy and clinical hypnosis for vasomotor symptoms. It does not make every form of counseling or coaching equivalent to those studied approaches. A useful question is what the proposed service actually involves and which outcome its evidence supports. That is more informative than applying the word behavioral to the entire program.
General health support is not the same as a hot-flash claim
Nutrition counseling, fitness services and bone-health programming appear in Utah’s public menu. They may be discussed for health goals other than vasomotor symptoms. This review does not assign those programs a hot-flash benefit simply because they are offered alongside menopause treatment.
The NAMS abstract evaluates interventions for vasomotor symptoms and does not recommend supplements or herbal remedies for that purpose. Its scope does not amount to a judgment on every service a health system provides. The Cleveland Clinic review explores a similar distinction between a broad clinic discussion and evidence supporting one particular symptom claim.
A preference list can explain priorities without deciding treatment
Utah’s appointment-preparation page asks about health goals, questions, past treatment experiences and preferences. It also requests medicine and supplement history. Those details can help a clinician understand what matters to the patient and why an earlier approach was unacceptable or unsuccessful.
They are not a self-selection form that establishes eligibility. The medicine-families guide explains why products grouped under nonhormonal can still have different purposes and restrictions. Utah’s page does not identify an exact product from the preference list. A clinician must still determine whether a proposed intervention fits the symptoms, relevant history and other medicines.
Complex history is a reason for assessment, not blanket clearance
Utah’s program page discusses specialist referral for histories such as estrogen-sensitive cancer, heart disease, stroke and blood clots. That supports access to a more detailed assessment; it does not establish that any nonhormonal option is automatically safe after those conditions. The label and individual evaluation remain important if a medicine is proposed.
As a separate example, the FDA’s fezolinetant safety communication describes serious liver risk and testing responsibilities. The Mayo review considers the additional limits of a cancer-survivorship consultation. This does not confirm that Utah offers that drug. It shows why the absence of hormones is not a complete safety description and why a prospective patient needs the actual medicine identified before its requirements can be discussed.
Records support the conversation; they do not replace it
The visit information asks for prior tests, screenings and personal and family health history. It describes a clinician reviewing concerns and deciding whether further evaluation is appropriate. Having an earlier result available is not evidence that it answers the present question or that more testing is always needed.
The UCLA review considers how a multidisciplinary assessment can divide concerns among several clinicians. Utah’s broad service list likewise leaves coordination questions: which clinician is addressing which goal, who explains the findings, and what follow-up is needed? The public preparation instructions do not supply those individual answers or a drug-monitoring timetable.
The remaining access questions are practical and specific
Utah documents a midlife menopause program and publishes appointment information. Neither page establishes a complete visit, medicine and follow-up price for the reader or nationwide remote treatment. Confirming the service location, appointment availability and applicable coverage is separate from confirming the clinical topic. An estimate should identify which services it includes rather than implying that one consultation charge covers testing, specialist visits or medicines.
The supported conclusion is that nonhormonal care can be discussed within this program. The unresolved details include the actual treatment, its purpose, individual safety assessment and ongoing responsibilities. Keeping those open questions visible allows the broad menu to be useful without presenting it as a guarantee of symptom relief or a ready-made prescription.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- University of Utah Health — Midlife Women’s Health and Menopause ProgramOfficial clinical service description, accessed September 29, 2026; an individual prescription, access arrangement, full price and outcome are not established. Published treatment categories are not an all-product formulary. · Checked 2026-09-29
- The 2023 nonhormone therapy position statement of The North American Menopause Society — PubMed abstractPrimary professional position-statement abstract, published 2023; vasomotor-symptom scope only. Full article not retrieved. Predates later drug approvals; does not evaluate these clinics or equate all forms of counseling. · Checked 2026-09-29
- University of Utah Health — What to Expect at Your Midlife AppointmentOfficial clinical location or appointment information, accessed September 29, 2026; regional access and preparation are distinct from medicine eligibility or monitoring. · Checked 2026-09-29
- FDA — Fezolinetant serious liver-injury safety communicationFederal primary safety communication; the retrieved text displays the September 12, 2024 communication. Used for serious liver-risk and testing context only; current boxed warning and contraindications are separately supported by the current exact DailyMed label where discussed. · Checked 2026-09-29